HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

WuXi AppTec (2359.HK/603259.CH) 2021Q3 - Logic Change?

Hangzhou Tigermed Consulting (3347.HK/300347.CH) - More of an Investment Company than a CRO

Wuxi Biologics (2269.HK) 2021Q3 - The Strength and the Concerns Behind the New Full-Year Guidance

Innovent Biologics (1801.HK) - The Strength and the Concerns

Pre-IPO Infervision Medical Technology - Insights on Industry, Business and Concerns

China Healthcare Weekly (Oct.8)-Summary of Concerns on Pharma Companies, VBP on TCM, Q4 PD-1 Bidding

Gravity Works As WeWork Doesn't; Now Plan B

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/lianbio" target="_blank" data-smartkarma-citation="entities:34478:1" rel="noopener">LianBio (LIAN US)</a> is about to officially list on NASDAQ. Based on license-in mode, LianBio has assembled a pipeline of nine assets across five therapeutic areas in less than three years, covering cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. In fact, as of mid-August this year, LianBio ranked first among domestic pharmaceutical companies in terms of the number of license-in projects with five new drugs. The late-stage development pipeline is led by mavacamten, infigratinib, TP-03, NBTXR3 and LYR-210, which would be commercialized in Greater China and other Asian markets. This insight mainly analyzed these late-stage candidates as well as the concerns of the Company.</p>

LianBio (LIAN US) is about to officially list on NASDAQ. Based on license-in mode, LianBio has assembled a pipeline of nine assets across five therapeutic areas in less than three years, covering cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. In fact, as of mid-August this year, LianBio ranked first among domestic pharmaceutical companies in terms of the number of license-in projects with five new drugs. The late-stage development pipeline is led by mavacamten, infigratinib, TP-03, NBTXR3 and LYR-210, which would be commercialized in Greater China and other Asian markets. This insight mainly analyzed these late-stage candidates as well as the concerns of the Company.

Pre-IPO LianBio (LIAN.US) - The Strength and the Concerns